CING: Ascending Triangle detected on 11 Mar 2026
Overall Score
91
of 100
Exceptional
Win Probability
77%
High
Reward / Risk
3.2
: 1
$0.19 reward
$-0.06 risk
Current Setup
CING is forming an ascending triangle with near-term bullish continuation, supported by three white soldiers confirmation (March 6–March 11). At 7.87, the stock trades 0.26 points below resistance at 7.61 and 1.62 points above support at 6.25. Pattern quality scores exceptionally high: structure 15.0/15, breakout 13.0/13, volume 12.0/12 for a combined 40/40 on pattern quality and 91/98 overall. Volume ratio of 1.49x average on 493,680 shares confirms institutional participation. RSI at 67.57 shows strength without overbought extremes (>70 threshold). Win probability of 77.41% indicates strong technical setup.
Stock Context
CING earnings are scheduled for March 18, 2026, creating immediate catalyst risk within days of this pattern setup. However, the FDA accepted the NDA for CTx-1301 with a PDUFA date of May 31, 2026, representing major regulatory validation. CTx-1301 clinical trials demonstrated positive topline data with a favorable effect compared to placebo. Three analysts rate CING as 'Strong Buy' with a 2026 price target of $31.33, significantly above current levels. A $12 million PIPE financing closed January 26, 2026 at $5.04/share led by Falcon Creek Capital, extending cash runway but creating shareholder dilution. ADHD medication sales in the U.S. have increased ~8% annually since 2010, reaching ~$18 billion in 2020, supporting market tailwinds for approval.
What to Expect
A successful breakout above 7.61 resistance targets a measured move to 8.27 (conservative target), derived from pattern geometry. Higher analyst price targets of $31.33 suggest significant runway if fundamental milestones deliver. Volume must sustain above 1.5x relative volume on breakout confirmation; declining volume on a push through resistance signals false breakout risk. Pattern invalidation occurs below support at 6.25, which would negate the ascending triangle setup and likely trigger stop-loss cascades given 77% win probability priced into current positioning. Three-month performance of +97.24% reflects this rally already being substantially extended.
Risk Factors
Cingulate reported Q3 2025 net loss of $4.8 million exceeding estimates, followed by $7.3 million loss in subsequent periods, reflecting ongoing operational challenges. Q3 cash was $6.1M with working capital of $1.55M; the company projects cash runway into Q2 2026 and requires ~$7.0M to advance commercialization, creating dilution risk. Biotechnology sector regime is bearish (-0.23), contrasting with neutral broader market (0.18), adding headwind. Earnings announcement March 18 arrives during pattern consolidation, introducing binary volatility risk. RSI at 67.57 approaches overbought territory; beta of 0.7 provides downside cushion but limits hedge value in sector correction.
Sources:
CING: Cingulate Inc - Stock Price, Quote and News - CNBC
·
Cingulate (CING) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026
·
Cingulate Stock Price Forecast. Should You Buy CING?
·
CING - Cingulate Inc Latest Stock News & Market Updates
·
Cingulate Inc. (CING) Stock Price, News, Quote & History - Yahoo Finance
·
Cingulate Inc (CING)
·
Cingulate Inc. (CING) Stock Forecast & Price Prediction 2026–2030 | CoinCodex
·
CING Stock Forecast 2026 - Cingulate Price Targets & Predictions
·
Cingulate closes $12M PIPE at Nasdaq market price | CING Stock News
·
Cingulate (CING) Stock Price, News & Analysis $CING
·
Cingulate Inc. (CING) Stock Price, News, Quote & History - Yahoo Finance
·
CING: Cingulate Inc - Stock Price, Quote and News - CNBC
·
Cingulate (CING) Stock Price, News & Analysis $CING
·
CING: Cingulate Inc Latest Stock Price, Analysis, News and Trading Ideas
·
Cingulate (CING) Stock Price & Overview
·
Cingulate Inc. (CING) Stock Price, Quote, News & Analysis | Seeking Alpha
·
CING - Cingulate Inc Latest Stock News & Market Updates
·
Cingulate Inc. Common Stock (CING) Stock Price, News, Quotes, & Historic Data | Nasdaq
·
Cingulate Inc. (CING) Earnings Dates & Report | Seeking Alpha
·
Cingulate Inc (CING)
Market & Sector Regime
Market
Neutral
0.18
-1.0
0
+1.0
Health Care Sector
Bearish
-0.24
-1.0
0
+1.0
Other Patterns Detected Today
Bull Flag
39 days in pattern
Good
30.7
Rounding Bottom
180 days in pattern
Strong
35.1
Three White Soldiers
3 days in pattern
Good
31.2
Overall Score
40
of 40
Pattern Quality
20
of 20
Setup
15
of 20
R/R
16
of 18
Context
Pattern Quality Score
15
of 15
Structure
13
of 13
Breakout
12
of 12
Volume
Recent Performance
Momentum & Trend
RSI (14)
67.6
Neutral
MACD Histogram
+0.05
Bullish
Bollinger Band Position
128.5%
Upper Band
Volatility & Risk
20-Day Volatility
0.90
Very High
ATR %
7.2%
High
Beta
0.70
Below Mkt
Volume Analysis
Volume Ratio
1.49x
Above Avg
20-Day Avg Vol
332K
shares / day
Current Volume
494K
shares traded
Price Levels
Target
$8.27
52W High
$7.92
Current
$7.87
Resistance
$7.61
Stop Loss
$7.15
Support
$6.25
52W Low
$3.20
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.